WX390

Phase 3Small molecule

SShanghai Jiatan Pharmatech Co., Ltd

WX390 is one of 62 small molecule programs targeting Cervical Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical AdenocarcinomaActive, not recruiting

Cervical CancerActive, not recruiting

Cervical AdenocarcinomaPhase 2

Active, not recruiting

Cervical CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

8 2

Camptosar

Pfizer

Phase 3

4 3

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 4

Emend IV

Merck & Co.

Phase 3

1 5

Trexall

Alnylam Pharmaceuticals

Phase 3

1 6

Hycamtin

GGynecologic Oncology Group

Phase 3

7 7

Adrucil

EElorac, Inc.

Phase 3

3 8

Blenoxane

SSequus Pharmaceuticals

Phase 3

1 9

Rescue Medications

Merck & Co.

Phase 3

1 10

Platinum Based Chemotherapy

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Cervical Adenocarcinoma

NCT06124963

Q2 2030

Phase 3Not yet recruiting

Cervical Cancer

NCT07392060

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors

Recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 1/2·NCT06117566·100 enrolled

A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations

Completed·SShanghai Jiatan Pharmatech Co., Ltd·Phase 1/2·NCT06132932·38 enrolled

A Study of WX390 in Patients With Advanced Solid Tumors

Recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 2·NCT06117540·70 enrolled

Cervical Cancer1 trial

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Not yet recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 3·NCT07392060·440 enrolled

Cervical Adenocarcinoma1 trial

A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations

Recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 2·NCT06124963·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for WX390. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — WX390 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for WX390. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Jiatan Pharmatech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Jiatan Pharmatech Co., Ltd

WX390

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Trials by Indication[1]

Patients With Advanced Solid Tumors3 trials

Cervical Cancer1 trial

Cervical Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News